Redox Biology in COPD

慢性阻塞性肺病中的氧化还原生物学

基本信息

项目摘要

DESCRIPTION (provided by applicant): PROJECT SUMMARY/ABSTRACT It is well known that oxidative stress contributes to the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD). However, the exact mechanism whereby changes in the oxidative environment contribute to disease has remained a "black box", and methods to detect specific oxidative modifications in target proteins have been limited. The adverse molecular actions of oxidants have largely been attributed to their role in causing damage. Yet, the concept that oxidants are molecules with regulatory functions important in normal cell and tissue homeostasis has also emerged. The latter signaling function of oxidants has been attributed to cysteine oxidations, such as S-nitrosylation (PSNO), and S-glutathionylation (PSSG). Recent work from our laboratory has determined that PSNO and PSSG are important biochemical events that limit the activation of the pro-inflammatory and pro-survival transcription factor, nuclear factor kappa B (NF-kB) in lung epithelial cells. Importantly, activation of NF-kB has been observed in patients with COPD and is believed to contribute the inflammatory process observed in these patients. To this date, information about changes in the homeostasis of PSNO and PSSG in lungs of patients with COPD, and the interplay between these events, remains largely absent, due to the difficulties to detect these oxidative modifications in situ in tissues. Our laboratory has recently developed two new assays that, for the first time, enable the detection of PSNO and PSSG in paraffin-embedded sections in situ. These recent observations and novel approaches lead us to hypothesize that the homeostasis of PSNO and PSSG is affected in lung tissues from patients with COPD, and that these changes correlate with regional patterns of NF-kB activation. In Specific Aim #1, we will determine the extent of PSNO and PSSG in lung biopsies of patients with COPD. We will utilize the recently developed chemical and catalytic cysteine derivatization strategies to monitor patterns in PSNO and PSSG in paraffin-embedded biopsy specimens from patients with varying severities of COPD using confocal laser scanning microscopy. We will also evaluate normal tissue derived from patients undergoing surgery for lung cancer resection. We will also further validate our assays and implement internal standards in order to improve their diagnostic utility. We will measure expression of glutaredoxin-1 (Grx1) and S-nitrosoglutathione (GSNO) reductase, as these enzymes represent the major regulators of PSSG and PSNO content, respectively. In Specific Aim #2 we will determine whether changes in PSNO and PSSG of NF-kB pathway members can be detected in patients with COPD. Completion of these Specific Aims represents an important validation of the utility of the new assays to detect PSNO and PSSG in tissues in situ. Finalization of this project will yield new insights into the extent to which various cysteine oxidations occur in patients with COPD, and provide insights into their relationship with the status of activation of NF-kB. (End of Abstract) PUBLIC HEALTH RELEVANCE: PROJECT NARRATIVE it is well known that oxidants contribute to damage of lungs of patients with Chronic Obstructive Pulmonary Disease (COPD). However, the exact cellular effects of oxidants have remained unclear which is problematic, because is does not enable investigators to determine whether antioxidant therapies were adequately effective. This laboratory has developed new assays which allow investigators for the first time to study the subtle action of oxidants in tissue slides prepared from lungs. This grant proposal therefore has as its major goal to test the utility of these two new assays to detect oxidative changes in normal lung as well as in lung tissue prepared from patients with increasing severities of COPD. If successful, these new assays may have diagnostic use in testing the extent of oxidative stress in patients with lung disease, and also in determining the effectiveness of antioxidant therapies. Completion of this grant proposal may also offer new insights into the mechanisms whereby oxidants regulate the severity of inflammation.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yvonne M. W. Janssen-Heininger其他文献

Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment
小分子介导的氧化还原酶 ERO1A 的抑制通过损害肿瘤微环境中的血管内皮生长因子和程序性死亡配体 1 来抑制侵袭性乳腺癌
  • DOI:
    10.1038/s41419-025-07426-1
  • 发表时间:
    2025-02-17
  • 期刊:
  • 影响因子:
    9.600
  • 作者:
    Ersilia Varone;Michele Retini;Alessandro Cherubini;Alexander Chernorudskiy;Alice Marrazza;Andrea Guidarelli;Alfredo Cagnotto;Marten Beeg;Marco Gobbi;Stefano Fumagalli;Marco Bolis;Luca Guarrera;Maria Chiara Barbera;Chiara Grasselli;Augusto Bleve;Daniele Generali;Manuela Milani;Michele Mari;Mario Salmona;Giovanni Piersanti;Giovanni Bottegoni;Massimo Broggini;Yvonne M. W. Janssen-Heininger;Jaehyung Cho;Orazio Cantoni;Ester Zito
  • 通讯作者:
    Ester Zito

Yvonne M. W. Janssen-Heininger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yvonne M. W. Janssen-Heininger', 18)}}的其他基金

Glutaredoxin, Glutathione Metabolism and Lung Cancer
谷氧还蛋白、谷胱甘肽代谢与肺癌
  • 批准号:
    10657945
  • 财政年份:
    2023
  • 资助金额:
    $ 7.53万
  • 项目类别:
Collagen Oxidation, Myofibroblast Activation and Age-Associated Pulmonary Fibrosis
胶原蛋白氧化、肌成纤维细胞激活和年龄相关性肺纤维化
  • 批准号:
    10532853
  • 财政年份:
    2022
  • 资助金额:
    $ 7.53万
  • 项目类别:
Collagen Oxidation, Myofibroblast Activation and Age-Associated Pulmonary Fibrosis
胶原蛋白氧化、肌成纤维细胞激活和年龄相关性肺纤维化
  • 批准号:
    10445737
  • 财政年份:
    2021
  • 资助金额:
    $ 7.53万
  • 项目类别:
2020 Oxygen Radicals Gordon Research Conference (GRC) and Gordon Research Seminar (GRS)
2020年氧自由基戈登研究会议(GRC)和戈登研究研讨会(GRS)
  • 批准号:
    9912443
  • 财政年份:
    2020
  • 资助金额:
    $ 7.53万
  • 项目类别:
S-glutathionylation chemistry in fibrotic lung remodeling
纤维化肺重塑中的 S-谷胱甘肽化学
  • 批准号:
    10585922
  • 财政年份:
    2017
  • 资助金额:
    $ 7.53万
  • 项目类别:
S-glutathionylation chemistry in fibrotic lung remodeling
纤维化肺重塑中的 S-谷胱甘肽化学
  • 批准号:
    10320789
  • 财政年份:
    2017
  • 资助金额:
    $ 7.53万
  • 项目类别:
Redox-based Fas signaling in allergic airway disease
过敏性气道疾病中基于氧化还原的 Fas 信号传导
  • 批准号:
    7822474
  • 财政年份:
    2009
  • 资助金额:
    $ 7.53万
  • 项目类别:
Epithelial JNK-TGFb1 Signaling Axis in Airway Remodeling
气道重塑中的上皮 JNK-TGFb1 信号轴
  • 批准号:
    7367482
  • 财政年份:
    2008
  • 资助金额:
    $ 7.53万
  • 项目类别:
Epithelial JNK-TGFb1 Signaling Axis in Airway Remodeling
气道重塑中的上皮 JNK-TGFb1 信号轴
  • 批准号:
    7644952
  • 财政年份:
    2008
  • 资助金额:
    $ 7.53万
  • 项目类别:
Epithelial JNK-TGFb1 Signaling Axis in Airway Remodeling
气道重塑中的上皮 JNK-TGFb1 信号轴
  • 批准号:
    8459777
  • 财政年份:
    2008
  • 资助金额:
    $ 7.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了